Search Results
Your search for ,New matches 16913 pages
Showing 11501 - 11550Trastuzumab Biosimilar Shows Efficacy and Safety Comparable to Reference Product in Phase III HERITAGE Trial
A new biosimilar version of the monoclonal antibody trastuzumab (Herceptin) is getting close to the finish line in the race to develop biosimilars in oncology. The new antibody, MYL-1401O, demonstrated comparable efficacy and safety compared with trastuzumab as front-line treatment of women with...
ASCO Releases the Updated Version of Its Value Framework
Last June, ASCO published its initial concept for a value framework in the Journal of Clinical Oncology (JCO).1 The framework, developed by ASCO’s Value in Cancer Care Task Force, is designed to provide a standardized approach to assist physicians and patients in assessing the “value” of a new...
Expert Point of View: Dominique Valteau-Couanet, MD, PhD
Study discussant Dominique Valteau-Couanet, MD, PhD, of the Gustave Roussy in France, said the study was “an important step” in research, by showing “Cy-THIO/mCEM [tandem autologous stem cell transplant (ASCT) with cyclophosphamide/thiotepa followed by a modified regimen of...
Low-Dose CT Screening May Detect New Solid Nodules and Lung Cancer Probability
As reported by Walter et al in The Lancet Oncology, incidence screening with low-dose computed tomography (CT) in high-risk individuals detected new solid nodules in approximately 5% to 7% at second and third screenings in the ongoing Dutch-Belgian NELSON trial. Larger nodule size was associated...
Final Results of METEOR Trial Show Cabozantinib Improves Overall Survival vs Everolimus in Advanced RCC
As reported by Choueiri et al in The Lancet Oncology, the final results of the phase III METEOR trial indicate significantly improved overall survival with cabozantinib (Cabometyx) vs everolimus (Afinitor) in patients with advanced renal cell carcinoma (RCC) that had progressed after previous...
Report Finds Families of Cancer Survivors Challenged by Intense, Episodic Caregiving Experiences
A new report shows that people caring for a loved one with cancer often have more intense, episodic caregiver responsibilities than those caring for someone with other health needs. The report, from the National Alliance for Caregiving in partnership with the National Cancer Institute and the...
Genomic Classification and Outcome in Acute Myeloid Leukemia
As reported in The New England Journal of Medicine, Papaemmanuil et al have identified 11 genomic subgroups in acute myeloid leukemia (AML) associated with distinct diagnostic features and clinical outcomes. AML Subgroups The study included analysis of driver mutations in 111 cancer genes and...
SNMMI 2016: VASH Collimator Allows Three-Dimensional Imaging of the Breast With Less Radiation
Preliminary tests have demonstrated that a new device may enable existing breast cancer imagers to provide up to six times better contrast of tumors in the breast, while maintaining the same or better image quality and halving the radiation dose to patients. The advance is made possible by a new...
Protein Could Help Identify Chronic Graft-vs-Host Disease
A new study published by Kariminia et al in the journal Blood has identified a protein that could diagnose chronic graft-vs-host disease in patients undergoing blood and bone marrow transplantation. The work was led by researchers in the Michael Cuccione Childhood Cancer Research Program at BC...
Japanese Trial Shows Improved Survival With Adjuvant S-1 vs Gemcitabine in Resected Pancreatic Cancer
Updated results of a Japanese phase III trial (JASPAC 01) reported in The Lancet by Uesaka et al showed that adjuvant S-1 was associated with significantly better overall survival compared with gemcitabine in patients with resected pancreatic cancer. Study Details In the open-label noninferiority ...
SNMMI 2016: Pretargeted Radioimmunotherapy Eliminates Colorectal Cancer in Preclinical Studies
Presenters at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI) unveiled a novel radioimmunotherapy that combines a cancer-seeking antibody with potent radionuclide agents, resulting in complete remission of colorectal cancer in mouse models (Scientific Paper...
Study Finds Inotuzumab Ozogamicin Improves Outcomes vs Standard Therapy in Relapsed/Refractory ALL
In a phase III trial reported in The New England Journal of Medicine, Kantarjian et al found that treatment with the antibody-drug conjugate inotuzumab ozogamicin resulted in a greater complete remission rate and improved overall survival vs standard therapy in patients with relapsed/refractory...
SNMMI 2016: CT-Based Lean Body Mass Calculations Improve Accuracy of PET for Patients With Cancer
Patients with cancer often experience significant fluctuations in weight and lean body mass. Neglecting to account for these changes can prevent clinicians from obtaining precise data from molecular imaging, but a new method of measuring lean body mass takes changes in individual body...
ASCO 2016: Nivolumab Extends Survival for Patients With Advanced Renal Cell Carcinoma Treated Beyond Disease Progression
In a large randomized study, the immunotherapy drug nivolumab (Opdivo), an anti–PD-1 (programmed cell death protein 1) monoclonal antibody, was shown to be a safe and effective therapy for kidney cancer even in patients who continued treatment after their disease progressed. Results ...
MD Anderson Receives $10.6 Million From CPRIT for Lung Cancer Research
The University of Texas MD Anderson Cancer Center will receive $10.6 million in funding from the Cancer Prevention and Research Institute of Texas (CPRIT) for two collaborative studies targeting crucial issues in lung cancer. The two multi-investigator research awards, designed to support teams of...
FDA Approves New Diagnostic Imaging Agent to Detect Rare Neuroendocrine Tumors
The U.S. Food and Drug Administration (FDA) has approved Netspot, the first kit for the preparation of Ga-68 dotatate injection, a radioactive diagnostic agent for positron-emission tomography (PET) imaging. This radioactive probe will help locate tumors in adult and pediatric patients with...
ASCO Value in Cancer Care Task Force
The Value in Cancer Care Task Force was established in 2007 to educate oncologists about the importance of discussing costs associated with recommended treatments, empower patients to ask questions about the anticipated costs of their treatment options, identify the drivers of the rising costs of...
Yale Researchers Win Sokoloff Family-Melanoma Research Alliance Award
A new approach to understanding why T cells are often too weak to fight and destroy tumor cells has earned Yale Cancer Center researchers team science award from the Sokoloff Family-Melanoma Research Alliance. The $900,000 award will fund research over 3 years examining metabolic regulation of ...
AUA Honors Its 2016 Annual Award Winners
The American Urological Association (AUA) honored its 2016 AUA award recipients during its 111th Annual Meeting in San Diego, Calfornia. These physician researchers, educators, and organizations were honored for their contributions to the field of medicine, the specialty of urology, and the AUA....
The Importance of Listening to Patients
My experience with cancer, or more accurately, cancers, is complicated. In 2002, after returning from a medical mission to Honduras, I noticed a bean-sized lymph node above my left clavicle. As an oncology-certified nurse, I knew not to ignore any unusual nodules that pop up on the body and asked...
Rising
There were once two patients with leukemia. Other than their diagnoses and their ages, these two men had nothing in common. Meet Michael Michael was an artist—a sculptor. He had large, sensitive, blue eyes and a quiet, pensive manner. His acute observational power led him to ponder deep questions...
University of Maryland Greenebaum Cancer Center Designated as NCI Comprehensive Cancer Center
The University of Maryland Marlene and Stewart Greenebaum Cancer Center has been awarded the National Cancer Institute’s (NCI’s) highest designation as a Comprehensive Cancer Center. The prestigious distinction recognizes the cancer center’s high caliber of scientific leadership and robust programs ...
HOPA Research Grants Announced, Totaling Nearly $60,000 in Funding
The Hematology/Oncology Pharmacy Association (HOPA) has awarded two HOPA Research Grant Awards to Val Adams, PharmD, BCOP, FCCP, and Jill S. Bates, PharmD, MS, BCOP, for their respective research projects. The goal of HOPA’s Research Grant efforts are to fund work that results in facilitating...
The Best HCAHPS Score: A Rodeo Invitation
An otherwise healthy, actively working, independent 60-year-old patient came to us with a several months’ history of abdominal pain. He had been seen by other physicians prior to coming to us for a second opinion. Our workup revealed a large cystic lesion emanating from the pancreas but involving ...
Low-Dose Chemical Exposure and Cancer
According to estimates from the World Health Organization (WHO) and the International Agency for Research on Cancer (IARC), environmental toxic exposures are responsible for between 7% and 19% of human cancers. However, the 2008–2009 President’s Cancer Panel Annual Report estimated that the “true...
FDA Approves New Diagnostic Imaging Agent to Detect Recurrent Prostate Cancer
On May 27, the U.S. Food and Drug Administration (FDA) approved fluciclovine F-18 (Axumin), a radioactive diagnostic agent for injection. Fluciclovine F-18 is indicated for positron-emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated...
Clinical Trials Actively Recruiting Patients With Liver Cancer
Pilot Study Title: Pilot Study of Hepatic Arterial Infusion Therapy in Patients With Unresectable or Borderline Resectable Intrahepatic Cholangiocarcinoma Study Type: Interventional/nonrandomized/parallel assignment Study Sponsor and Collaborators: Washington University School of Medicine Purpose: ...
Multi-Institutional Metastatic Melanoma Research Team Receives $900,000 L’Oréal Paris USA–MRA Team Science Award for Women in Scientific Research
An international, multi-institutional research team consisting of the Spanish National Cancer Research Centre (CNIO); The Wistar Institute; Cancer Research UK Edinburgh Centre; the Perelman School of Medicine at the University of Pennsylvania; and the Icahn School of Medicine at Mount Sinai has...
SIRIUS Trial Heralds a New Era of Promise in Treating Resistant Myeloma
Multiple myeloma cells uniformly overexpress CD38.1 Daratumumab (Darzalex), a CD38-targeting human IgG1 kappa monoclonal antibody, has been evaluated in a series of phase I/II trials involving patients with relapsed or relapsed and refractory myeloma who have received at least two or more prior...
American Cancer Society Report Assesses Progress Against Goals Set for Nation 25 Years Ago
A new report assesses how the nation fared against the ambitious goal set by the American Cancer Society (ACS) to reduce cancer death rates by 50% over 25 years ending in 2015. The report finds areas where progress was substantial, and others where it was not. Published by Byers et al,1 the report ...
ASCO 2016: CancerLinQ Extends Its Reach, Announces New Partnerships
ASCO announced that a total of 58 practices in 39 states and the District of Columbia have joined CancerLinQ™, ASCO’s big data initiative to rapidly improve the quality of care for people with cancer. CancerLinQ is already up and running in a number of practices and drawing on approximately...
Prostate Cancer: Opinions Vary on Gleason Scores and Surgery
Diagnosis and treatment of prostate cancer have been the source of heated debate for decades, most of which has centered on the clinical value of the prostate-specific antigen (PSA) test. In 2012, the U.S Preventive Services Task Force (USPSTF) gave the PSA test a D grade, which discourages many...
Lung Cancer Alliance Supports Two Young Investigator Awards
The Conquer Cancer Foundation of ASCO (CCF) has received generous support from Lung Cancer Alliance to fund a 2016 and 2017 Young Investigator Award (YIA) in lung cancer. Lung Cancer Alliance has a more than 20-year history of working to save lives and advance research by empowering those living...
Peter H. Wiernik, MD, Receives 2016 Walter Reed Distinguished Achievement Award From UVA Medical
The University of Virgina (UVA) Medical Alumni Association has recognized Peter H. Wiernik, MD, as co-recipient of its 2016 Walter Reed Distinguished Achievement Award. Dr. Wiernik received the award along with Charles W. Cummings, MD, former Chair of the Department of Otolaryngology–Head and Neck ...
Stephen K. Burley, MD, DPhil, Named Co–Program Leader at Rutgers
Stephen K. Burley, MD, DPhil, has been named as Co–Program Leader of the Cancer Pharmacology Research Program at Rutgers Cancer Institute of New Jersey. This basic science program unites investigators with broad scientific expertise who share a strong interest in cancer pharmacology and preclinical ...
QOPI Certification Program Certifies First International Practice
ASCO recently announced that the Contemporary Oncology Team of Athens, Greece, as part of the new international pilot project, is the first international practice to receive Quality Oncology Practice Initiative (QOPI®) certification through the QOPI Certification Program, LLC (QCP). “Achieving...
Anti–PD-1 Inhibitor Gains Foothold in Merkel Cell Carcinoma
Immunotherapy marches on! One of the latest frontiers for checkpoint inhibitors is the treatment of Merkel cell carcinoma, a rare but aggressive type of cancer. First-line therapy with pembrolizumab (Keytruda)—an anti–PD-1 (programmed cell death protein 1) inhibitor—achieved an objective response...
Richard J. O’Reilly, MD, Named The Society of MSK’s Inaugural Prize Winner for Groundbreaking Contributions in Pediatric Oncology
The Society of Memorial Sloan Kettering Cancer Center (MSK) has announced that Richard J. O’Reilly, MD, has been named the inaugural recipient of The Society of Memorial Sloan Kettering Prize. Founded in 1946, The Society of MSK is a volunteer-led organization within MSK dedicated to promoting the ...
Patient Advocate Michael Kaplan to Lead Melanoma Research Alliance
The Melanoma Research Alliance (MRA), the world’s largest private funder of melanoma research, has named Michael Kaplan as its new leader. For the past 20 years, Mr. Kaplan has headed various nonprofits and patient advocacy groups, including his most recent position as President and CEO of...
Lisa A. Carey, MD, and Ann Partridge, MD, MPH, Appointed Co-Chairs of the Alliance for Clinical Trials in Oncology Breast Committee
Lisa A. Carey, MD, of the University of North Carolina (UNC), and Ann Partridge, MD, MPH, of Dana-Farber Cancer Institute, have been appointed Co-Chairs of the Alliance for Clinical Trials in Oncology Breast Committee. The Alliance for Clinical Trials in Oncology develops and conducts cancer...
Ovarian Suppression in Premenopausal Women With Estrogen Receptor–Positive Breast Cancer
Oophorectomy was the first proposed form of endocrine therapy for women with breast cancer. Over 100 years ago, Thomas Nunn reported a relationship between menopause and regression of breast cancer.1 This incited interest in the induction of menopause as an anticancer therapy, and in 1986, a...
Improvement in Overall Survival With Addition of Chemotherapy to Radiotherapy in Low-Grade Glioma
Final results of the RTOG 9802 phase III trial reported in The New England Journal of Medicine by Jan C. Buckner, MD, of Mayo Clinic, Rochester, and colleagues, showed that the addition of chemotherapy with procarbazine, lomustine, and vincristine to radiotherapy significantly prolonged overall...
Nivolumab in Classical Hodgkin Lymphoma
On May 17, 2016, nivolumab (Opdivo) was granted accelerated approval for treatment of patients with classical Hodgkin lymphoma that has relapsed or progressed after autologous hematopoietic stem cell transplantation and post-transplantation brentuximab vedotin (Adcetris).1,2 Continued approval for ...
Statement From FDA Commissioner Robert Califf, MD, on the Release of the Final Individual Patient Expanded Access Form
On June 2, 2016, U.S. Food and Drug Administration (FDA) Commissioner Robert Califf, MD, issued the following statement on the release of the final individual patient expanded access form. “Today, the FDA finalized its efforts to streamline the process used by physicians to request expanded...
Atezolizumab in Platinum-Treated Advanced Urothelial Carcinoma: A New Standard of Care?
Compared with a historic control rate, a phase II study of the programmed cell death ligand 1 (PD-L1) inhibitor atezolizumab (Tecentriq) has demonstrated clinically meaningful responses in patients with urothelial carcinoma who progressed after platinum-based chemotherapy.1 Hailed as a “major...
Dr. William Morton and His Engineer
A Century of Progress The text and photograph on this page are excerpted from a four-volume series of books titled Oncology Tumors & Treatment: A Photographic History, by Stanley B. Burns, MD, FACS. The photo below is from the volume titled “The Antiseptic Era: 1876–1900.” To view additional...
Chemotherapy After Radical Prostatectomy May Benefit African Americans and High-Risk Patients
A new U.S. Department of Veterans Affairs (VA) study suggests that African American men and men with a higher tumor stage may benefit from adjuvant chemotherapy following radical prostatectomy.1 According to prespecified analysis of these two “high–risk” subgroups, patients with ≥ T3b disease had a ...
University of Catania Presents Margaret Foti Scholar-in-Training Award to Saverio Candido, PhD
The American Association for Cancer Research (AACR) congratulates Saverio Candido, PhD, on receiving the fourth Margaret Foti Scholar-in-Training Award from the University of Catania in Italy. Dr. Candido is being recognized for his research on biomarkers of bladder cancer development and...
Vice President Joe Biden Addresses Attendees at ASCO 2016 Annual Meeting
Vice President Joe Biden offered remarks on the White House’s National Cancer Moonshot Initiative on Monday, June 6, to attendees at the 2016 ASCO Annual Meeting in Chicago. Essential Elements “The Moonshot Initiative can be a vehicle for major new progress against cancer, and ASCO’s Annual...
Comparing Treatments by Efficacy, Toxicity, and Cost
Last year, five organizations introduced new methods to compare cancer treatments. For more on ASCO’s Value Framework, see page 120. The NCCN Evidence Blocks™ use a simple graphic to show experts’ ratings of systemic therapies in five areas: efficacy, safety, quality and quantity of evidence,...
